-
公开(公告)号：US11566082B2
公开(公告)日：2023-01-31
申请号：US15525688
申请日：2015-11-11
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav Rodrigo , Tomas Bjorkman , Mats Ander
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
-
公开(公告)号：US20210087227A1
公开(公告)日：2021-03-25
申请号：US17114773
申请日：2020-12-08
Applicant: CYTIVA BIOPROCESS R&D AB
Inventor： Gustav José Rodrigo , Tomas Bjorkman , Mats Ander
IPC: C07K1/22 , B01J20/26 , B01J20/285 , B01J20/286 , B01J20/32 , C07K14/31 , C07K16/00 , C07K16/12 , C07K17/10 , B01D15/38 , B01J20/24 , B01J20/28 , C07K16/06
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO: 51 or SEQ ID NO: 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号：US10889615B2
公开(公告)日：2021-01-12
申请号：US16096869
申请日：2017-05-10
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav José Rodrigo , Tomas Bjorkman , Mats Ander
IPC: C07K1/22 , B01J20/26 , C07K14/31 , C07K16/00 , B01J20/32 , B01J20/285 , B01J20/286 , C07K16/12 , C07K17/10
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号：US12221492B2
公开(公告)日：2025-02-11
申请号：US17149830
申请日：2021-01-15
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav Rodrigo , Tomas Bjorkman , Mats Ander
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
-
公开(公告)号：US20230331870A1
公开(公告)日：2023-10-19
申请号：US18093624
申请日：2023-01-05
Applicant: Cytiva Bioprocess R&D AB
Inventor： Gustav RODRIGO , Tomas Bjorkman , Mats Ander
CPC classification number: C07K16/46 , B01J20/289 , B01J20/3219 , B01J20/3274 , B01D15/3809 , C07K16/065 , C07K1/22 , C07K14/31 , C07K16/00
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
Patent Agency Ranking
公开(公告)号：US20230257417A1
公开(公告)日：2023-08-17
申请号：US18181974
申请日：2023-03-10
Applicant: Cytiva BioProcess R&D AB
Inventor： Annika Kristina Forss , Gustav Jose Rodrigo , Tomas Bjorkman , Jesper Ulf Hansson , Mats Ander
CPC classification number: C07K1/22 , C07K16/1271 , C07K17/10 , B01J20/286 , C07K14/31 , C07K16/065 , B01D15/00 , B01J20/3274 , B01J20/3212 , B01J2220/52
Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support: b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing said separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein the alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA).
-
公开(公告)号：US11667671B2
公开(公告)日：2023-06-06
申请号：US16911511
申请日：2020-06-25
Applicant: Cytiva BioProcess R&D AB
Inventor： Annika Forss , Mats Ander , Tomas Bjorkman , Hans Blom , Jesper Hansson , Gustav Rodrigo
IPC: C07K1/16 , C07K1/22 , C07K16/00 , B01J20/286 , B01J20/285 , B01D15/18 , B01D15/34 , C07K14/31
CPC classification number: C07K1/165 , B01D15/1807 , B01D15/1864 , B01D15/34 , B01J20/285 , B01J20/286 , C07K1/22 , C07K14/31 , C07K16/00 , C07K2317/21 , C07K2317/31 , C07K2319/30
Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of:
a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml;
b) contacting a liquid sample comprising an immunoglobulin with the separation matrix;
c) washing the separation matrix with a washing liquid;
d) eluting the immunoglobulin from the separation matrix with an elution liquid; and
e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.-
公开(公告)号：US11136357B2
公开(公告)日：2021-10-05
申请号：US16252015
申请日：2019-01-18
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav Rodrigo , Mats Ander , Tomas Bjorkman
IPC: C07K14/195 , C07K1/22 , C07K16/00
Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more mutated binding domains of Peptostreptococcus Protein L.
-
公开(公告)号：US10954309B2
公开(公告)日：2021-03-23
申请号：US15525688
申请日：2015-11-11
Applicant: Cytiva BioProcess R&D AB
Inventor： Gustav Rodrigo , Tomas Bjorkman , Mats Ander
Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
-
公开(公告)号：US20210017223A1
公开(公告)日：2021-01-21
申请号：US16981716
申请日：2019-03-26
Applicant: Cytiva BioProcess R&D AB
Inventor： Tomas Bjorkman , Bengt Westerlund
Abstract: The invention relates to a method of separating immunoglobulin variants, comprising the steps of: a) providing a column packed with an Fc-binding affinity chromatography resin; b) loading a sample comprising at least two Fc-comprising immunoglobulin variants onto the column; c) optionally washing the column with a washing liquid; and d) conveying an eluent through said column to elute at least a target immunoglobulin variant from said column and recovering one or more eluate fractions comprising the target immunoglobulin variant in enriched form.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.02 seconds)
